Alphatec Holdings, Inc. (NASDAQ:ATEC) Receives $17.11 Consensus Target Price from Brokerages

Alphatec Holdings, Inc. (NASDAQ:ATEC) has been given a consensus recommendation of “Moderate Buy” by the nine ratings firms that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $17.11.

ATEC has been the topic of a number of recent research reports. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Alphatec in a research note on Thursday, October 31st. Needham & Company LLC restated a “buy” rating and issued a $13.00 price objective on shares of Alphatec in a research report on Thursday, October 31st. Finally, Barclays lifted their price objective on Alphatec from $19.00 to $20.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 19th.

Alphatec Stock Performance

NASDAQ:ATEC opened at $9.06 on Friday. Alphatec has a twelve month low of $4.88 and a twelve month high of $17.34. The company has a market capitalization of $1.28 billion, a P/E ratio of -7.08 and a beta of 1.38. The company has a current ratio of 2.32, a quick ratio of 1.15 and a debt-to-equity ratio of 30.21. The firm has a 50-day moving average price of $9.05 and a two-hundred day moving average price of $8.05.

Hedge Funds Weigh In On Alphatec

A number of hedge funds have recently made changes to their positions in ATEC. XTX Topco Ltd purchased a new stake in Alphatec during the 3rd quarter worth $69,000. Net Worth Advisory Group acquired a new position in shares of Alphatec during the third quarter worth about $76,000. Van ECK Associates Corp grew its stake in shares of Alphatec by 57.0% in the third quarter. Van ECK Associates Corp now owns 19,273 shares of the medical technology company’s stock valued at $99,000 after buying an additional 6,998 shares in the last quarter. Tempus Wealth Planning LLC purchased a new stake in shares of Alphatec during the 3rd quarter valued at about $107,000. Finally, Atria Investments Inc lifted its position in Alphatec by 8.0% during the 3rd quarter. Atria Investments Inc now owns 19,609 shares of the medical technology company’s stock worth $109,000 after acquiring an additional 1,460 shares in the last quarter. Hedge funds and other institutional investors own 66.35% of the company’s stock.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.